聚二烯通过向神经炎症和氧化应激减轻MPTP诱导的神经毒性
Yepeng Fan1, Xin He1, Mulan Chen1
1Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.
Biochemical and biophysical research communications
|July 9, 2024
概括
固醇 (PTE) 在帕金森病 (PD) 治疗中表现有前途. 它通过减少炎症和氧化应激来保护大脑细胞. 在PD的小鼠模型中.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,其特点是运动缺陷.
- 固醇 (PTE),一种来自蓝的化合物,已知具有神经保护作用.
- 对于PTE在PD病变发生过程中的特定作用尚不完全理解.
研究的目的:
- 在帕金森病 (PD) 的动物模型中研究固 (PTE) 的神经保护潜力.
- 阐明PTE对神经炎症和PD中氧化应激的影响背后的机制.
主要方法:
- 利用1-甲基-4--1,2,3,6-四胺 (MPTP) 的小鼠模型诱导帕金森病类症状.
- 给MPTP治疗的小鼠服用甲 (PTE).
- 评估运动功能,多巴胺水平,多巴胺能神经元存活率和α-synuclein表达.
- 测量的神经炎症标志物 (微细胞/细胞激活,TNF-α,IL-1β) 和氧化应激 (ROS,MDA,TAOC,SOD).
主要成果:
- 在MPTP模型中,固醇 (PTE) 的使用逆转了多巴胺耗尽和改善了运动障碍.
- PTE减轻了多巴氨基神经元损失,并减少了α-synuclein上调.
- PTE抑制了微质细胞和天体细胞的激活,降低了促炎性细胞因子 (TNF-α,IL-1β).
- PTE降低了氧化应激标志物 (ROS,MDA) 和增加了抗氧化能力 (TAOC,SOD).
结论:
- 在MPTP诱导的帕金森病小鼠模型中,聚乙烯 (PTE) 显示出显著的神经保护作用.
- 通过抑制神经炎症和氧化应激,PTE可以改善PD症状.
- 固醇 (PTE) 是帕金森病的潜在治疗药物.
相关概念视频
01:24Parkinson's Disease: Treatment
251
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
251
01:22Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:15Parkinson's Disease: Overview
522
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
522
01:46Electron Transport Chain: Complex I and II
12.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.8K